Questions across 26 calls

Chintan Sheth

Girik Capital

Honasa Consumer Limited

Honasa Consumer Limited CC-Mar24.pdf · 2024-05-23

Hi. Thank you for the opportunity. I hope I'm audible.

Yes. Thank you. Congratulations, Team, for this great set of numbers. Couple of questions. One is on the Mamaearth growth. You mentioned the Euromonitor data, the secondary one growing at 21% for the Mamaearth brand. But for the full year, it looks like a single-digit or 9% to 10% growth. The gap you explained partly because of the distribution change. But if we just look at the expectation-wise, whether the brand can grow at a high 18%-20% growth rate or do you feel there is the online softn ess also coming through, the base is also hitting, which is reflecting in the softer number for us?

Gland Pharma Limited

Gland Pharma Limited CC-Dec23.pdf · 2024-02-14

I hope I'm audible. Again, I have a couple of questions on Cenexi. If -- you elaborated that inventory-related issues resulted in losses over there apart from the one-off part. But if you look at the gross margin profile sequentially, it has contracted only 200 basis points from 77 to 75. Does that actually translate into such a large under-absorption of profits or under-absorption of cost?

Okay. But the production loss of this quarter will also have some impact or element of reduced revenue in the upcoming quarter in 4Q. Will that be the right assessment? The pain will continue for another quarter. Do you think so?

Mankind Pharma Limited

Mankind Pharma Limited CC-Dec23.pdf · 2024-02-02

Sir, I have a similar question on the export side. Basically , the current run rate, you said the growth will not be similar to what we achieved this year because of certain opportunities we got. But do we see the positive trend to continue o r at least we can maintain or match the revenue trend of this year, continuing going forward in the absolute basis which is around Rs. 200 crores this quarter?

Mankind Pharma Limited CC-Sep23.pdf · 2023-11-01

A couple of questions. If you can, talk about the discontinuation of a few products. What is the impact on our sales during the quarter? And to ad d to it, what are our plans in terms of new product launches going forward? You mentioned one of the products in the OTC you are planning from the Panacea basket. If you can talk about that in terms of what is the pipeline, we are expected to see over the next 12 months or so?

Yes. The press release mentioned that softness in acute is also one of the reasons because a few products are being discontinued. If you can talk about what is the impact and what is the reason? Whether those products will come back on our table or not?

Angel One Limited

Angel One Limited CC-Dec23.pdf · 2024-01-16

Sir, on the affiliated channel partner side, if you can provide some more color what's your strategy around adding new set of adding new channel partners and whether that affiliated channel can be also leverage to expand your growth on the lending side of the business as well as your AMC side of the business in terms of distribution of the product, whether there will be an overlap to that, that will be the one. And second, on the on the margin front. Again, sorry to harp on that. But this upfronting of cost, if you can elaborate in terms of , if I look at the cost was slightly offset -- the increased cost is understandable. But at the same time, the cut the tariff also impacted the margins slight more than the increased cost. So the understanding would be that this is the last leg of tariff cut, which we can see or there is still you need to optimize it if the market in favor of in terms of adding more number of c lients. That will be the 2 questions.

What is this benchmark, LTV, you keep talking about what is the benchmark you keep the range, you keep in terms of is it linked to the income of that individual percentage of income of that individual? Or how should one look at the LTV for you? What is the LTV for you?

Angel One Limited CC-Sep23.pdf · 2023-10-13

Thank you for the opportunity. Yes. Sir, two set of questions. One is on a bit harping on the orders -- client orders and all. If you give us some colour on the trading difference between a mature client versus new client, as you already mentioned in your opening remarks that the mature , two-year older customer cohort is contributing more to our broking, net broking revenues. If you can provide color on how the mature clients trade or the order or quarterly order versus a new client, can you give some color that is, more business is comi ng. Obviously, intuitively, it looks like more business is coming. But how skewed it would be, that I would like to understand. And what kind of risks you foresee in terms of these orders softening down from the mature -- any thought process or any concern you have that this order might taper down in the upcoming future? That would be the question. And second, on the cost side, you did mention that we are in line with what we are spending right now. I believe there will be some thought process in terms of number of customer onboarding at an aggregate level, either be it share or in the overall demat accounts in the country, and post which, the need for spending more towards client acquisition will start to decline. So, any thought process around that, where the inflection point will come or the target that you have internally worked out. From that point onwards, the need for investing for client acquisition will start to taper off, if you can provide that understanding? These are the two set of questions. Thanks.

So repeat orders, I believe, will be based on the income they generate from trades, right? And given market is also supporting to some extent, the kind of ordering we are seeing right now looks like to follow through to continue. But what are -- from the Angel's point of view, the kind of information and the kind of future you are providing – whether, if you can give us how profitable this newer or mature cohorts independently? Whether they are making money, which brings them back to the trading activities -- is it what we are seeing currently? Or anything different you are reading there?